Hematopoietic cell transplantation for benign hematological disorders and solid tumors

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Hematopoietic cell transplantation (HCT) is established for aplastic anemia and hemoglobinopathies.
• HCT can correct autoimmune diseases and shows promise in hematological malignancies.
• Graft-versus-tumor effects observed in HCT for cancers inspire trials in solid tumors.

Purpose of the Study:

• To review the current status of HCT in treating benign hematological diseases.
• To update on HCT for severe autoimmune diseases.
• To discuss the application of HCT as immunotherapy for refractory solid tumors.

Main Methods:

• Review of nonmyeloablative conditioning for aplastic anemia with HLA-matched donors.
• Analysis of HCT outcomes for thalassemia major across different severity classes.
• Summary of autologous and allogeneic HCT for autoimmune diseases and solid tumors.

Main Results:

• Successful HCT outcomes for severe aplastic anemia, including unrelated donor transplants.
• Progress in HCT protocols for thalassemia major, aiming for broader patient eligibility.
• Demonstrated graft-versus-solid tumor effects in pilot trials for metastatic cancers.

Conclusions:

• HCT is a viable therapeutic option for various hematological and autoimmune conditions.
• Ongoing research expands HCT applicability, including nonmyeloablative approaches and immunotherapy.
• Further characterization of immune cells and targeting strategies are crucial for solid tumor HCT.